Novavax (NVAX) Highlights New Data from Novavax Phase 3 Prepare Trial of ResVax at 2019 IDSOG Meetings
- Wall Street closes lower as inflation fears prompt tech sell-off
- Dogecoin Sees 'Sell the News' Reaction to Musk's SNL Appearance, as 'Hustle' Comment is Weighed Against Launch 'To the Moon'
- Alphabet (GOOGL) and Facebook (FB) Downgraded to 'Neutral' at Citi as Decelerating Growth Is Not Bullish for Multiples
- Elliott Management has stake in Duke Energy (DUK) - WSJ
- Ethereum (ETH) Soars Above $4,000 to Print Fresh Record Highs
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Novavax, Inc. (NASDAQ: NVAX) today announced the presentation of new data from the company’s Prepare™ trial, a global Phase 3 clinical trial of ResVax™, an aluminum adjuvanted respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine. Geeta K. Swamy, M.D., Associate Professor of Obstetrics and Gynecology and Vice Dean and Associate Vice Provost for Scientific Integrity at Duke University, made the presentation at the 2019 IDSOG Annual Meeting held in Big Sky, Montana.
Dr. Swamy’s presentation included new observations based on the recently completed analyses of the 1-year safety data, including a 59.6% (95% CI 34.5, 71.7%) reduction in the incidence of serious adverse events (SAEs) diagnosed as pneumonia, with confirmation by chest x-ray, that extended through the first year of life. A similar efficacy of approximately 50% (95% CI 31.3, 62.7%) was found for all SAEs with a clinical diagnosis of pneumonia, also extending over a year. When x-ray-confirmed pneumonia SAEs associated with detection of RSV were considered, efficacy was 72.9% (95% CI. 45.7, 86.5%) through 180 days of life, the last time point at which active detection of RSV was carried out.
“Ongoing analysis of the Prepare trial data is teaching us more about how and where the vaccine was most efficacious in reducing RSV infections and its most severe complications,” said Louis F. Fries III, M.D., Chief Medical Officer of Novavax. “Based on the incidence rate for clinical pneumonia SAEs in placebo subjects in the Prepare trial and the vaccine’s efficacy in reducing this rate, ResVax could have a public health impact, in terms of vaccine-preventable disease incidence or number of women needed to vaccinate to prevent one case of infant pneumonia, that is similar or in excess of pneumococcal conjugate vaccines for similar outcomes. Such insights are valuable as we explore potential regulatory and clinical development paths forward to deliver an effective vaccine to address a serious global unmet need.”
Please click here to view a PDF of Dr. Swamy’s presentation along with other scientific presentations.
About ResVax™ and the Prepare Trial
ResVax is an RSV fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant. It is being developed to protect infants from RSV disease via maternal immunization, which may offer the best method of protection from RSV disease in infants through the first months of life. In February 2019, Novavax announced top-line data from Prepare™, a global Phase 3 clinical trial in 4,636 pregnant women, at least 3,000 of whom have received the vaccine, and their infants. Prepare is supported by an $89.1 million grant from the Bill & Melinda Gates Foundation (BMGF).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novavax (NVAX) Tops Q1 EPS by 55c, Revenues Beat
- Yalla Group Limited (YALA) Reports Q1 Revenues Beat; Provides 2Q Revenues Guidance Above Consensus
- UWM Holdings Corporation (UWMC) Reports Q1 EPS of $0.33
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Related EntitiesTwitter, Bill & Melinda Gates Foundation Trust
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!